A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in Germany. Open to participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.
Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 19th largest by enrollment, is one of 4 that started in 2012, is one of 12 in phase 3, and was the 11th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:
Duke University · Sites in United States, Germany, Italy and 1 more country
Ages 2–21
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 9 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 12 · Phase 4 2
First in 2004; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 52 across the 21 interventional studies. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 7 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
17 studies in Arthritis, Juvenile by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Arthritis, Juvenile by Hoffmann-La Roche, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2012, is one of 10 in phase 3, and was the 9th registered.
Hoffmann-La Roche’s Arthritis, Juvenile studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing tocilizumab in Arthritis, Juvenile, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 17 in Arthritis, Juvenile:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients aged 9-18 years with at least JIA ACR30 clinical response to RoActemra/Actemra in the core study will be eligible to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tocilizumab [RoActemra/Actemra]
Drug page: Tocilizumab
8 mg/kg iv every 4 weeks, 104 weeks
Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events
Adverse Events (AEs) and Serious Adverse Events (SAEs) were recorded from the first day of tocilizumab administration until 4 weeks after administration of the last dose of tocilizumab. AEs of special interest were Infections (including all opportunistic infections and non-serious infections as defined by those treated with IV anti-infectives), Myocardial infarction/Acute coronary syndrome, Gastrointestinal perforations and related events, Malignancies, Anaphylaxis/Hypersensitivity reactions, Demyelinating disorders, Stroke. Bleeding events, Hepatic events and Macrophage activation syndrome (MAS).
Time frame: Baseline and every 4 weeks up to Week 76 and Final Follow-Up Visit (up to 82 weeks)
Number of AEs of Special Interest and Study Drug Related AEs
AEs and SAEs were recorded from the first day of tocilizumab administration until 4 weeks after administration of the last dose of tocilizumab.
Time frame: Baseline and every 4 weeks up to Week 76 and Final Follow-Up Visit (up to 82 weeks)
Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90 by Visit
The six JIA ACR components comprised of: 1) Physician's global assessment of disease activity, 2) Parent/Participant's global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate (ESR) and/or C-reactive Protein (CRP), and 6) Childhood Health Assessment Questionnaire - Disease Index (CHAQ-DI). At an assessment visit, a JIA ACR30/50/70/90 response in comparison to Baseline was defined as: At least three of the six JIA ACR core components improving by at least 30 percent (%), 50%, 70%, or 90% respectively and no more than one of the remaining JIA ACR core components worsening by more than 30%.
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Percentage of Participants With Inactive Disease by Visit
A participant was defined to show inactive disease if all of the following criteria were applied: 1) No joints with active arthritis (no joints with swelling and no joints with lack of motion), 2) No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, 3) No active uveitis, 4) ESR and/or CRP within normal range, and 5) Physician's global assessment of disease activity equals (=) 0 millimeters (mm) on a Visual analog scale (VAS).
Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Percentage of Participants Achieving Clinical Remission (CR) at Each Visit
CR was defined as "clinical remission with medication (CRem)". A participant was in CR if inactive disease was observed for a minimum of 6 consecutive months.
Time frame: Baseline, Screening, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Visit (up to 82 weeks)
Physicians Assessment of Global Activity (VAS)
The participant's treating physician provided a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line, score 0 represented 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end score 100 represented 'arthritis very active'. A higher score indicated more disease activity.
Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Parent or Participant's Assessment of Global Activity (VAS)
The participant or parent/guardian, as appropriate, provided a rating of the participant's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line Score 0 represented 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end score 100 represented 'very poor' (ie, maximum arthritis disease activity). A higher score indicated poorer well-being.
Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Number of Joints With Active Arthritis
Joints with active arthritis were defined as joints with swelling or pain and limited of motion. The maximum number of joints with active arthritis was 71.The joint assessment was performed by an independent assessor who was not the treating physician and who was blinded to all other aspects of the participant's efficacy and safety data.
Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Number of Joints With Lack of Motion
Joints with lack of movement were assessed. The maximum number of joints with lack of movement was 67. The joint assessment was performed by an independent assessor who was not the treating physician and who was blinded to all other aspects of the participant's efficacy and safety data.
Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Erythrocyte Sedimentation Rate
ESR is a marker of inflammation and was measured as millimeters per hour (mm/h). Healthy individuals have low ESR. Higher ESR indicate inflammation.
Time frame: Baseline, Weeks 4, 8,12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Visit (up to 82 weeks)
CHAQ-DI Score
The CHAQ-DI questionnaire consisted of 30 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain had at least two component questions and if applicable to the participant there were four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do). The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).
Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72, and Final Follow-Up Visit (up to 82 weeks)
Parent or Participant's Assessment of Pain (VAS)
Parents or participants rated participant's pain by placing a horizontal line on a VAS of 0 (no pain)- 100 mm (severe pain).
Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72, and Final Follow-Up Visit (up to 82 weeks)
CRP Levels
CRP an acute phase protein, is a marker of inflammation. CRP was measured as milligrams per deciliter (mg/dL).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Follow-Up Visit (up to 82 weeks)
| Milestone | Tocilizumab 8 mg/kg |
|---|---|
| Started | 7 |
| Completed | 7 |
| Not completed | 0 |
Adverse Events (AEs) and Serious Adverse Events (SAEs) were recorded from the first day of tocilizumab administration until 4 weeks after administration of the last dose of tocilizumab. AEs of special interest were Infections (including all opportunistic infections and non-serious infections as defined by those treated with IV anti-infectives), Myocardial infarction/Acute coronary syndrome, Gastrointestinal perforations and related events, Malignancies, Anaphylaxis/Hypersensitivity reactions, Demyelinating disorders, Stroke. Bleeding events, Hepatic events and Macrophage activation syndrome (MAS).
| participants | Tocilizumab |
|---|---|
| Drug related AEs | 6 |
| Drug related SAEs | 0 |
| AEs of special interest | 1 |
| Drug-related AEs of special interest | 1 |
The six JIA ACR components comprised of: 1) Physician's global assessment of disease activity, 2) Parent/Participant's global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate (ESR) and/or C-reactive Protein (CRP), and 6) Childhood Health Assessment Questionnaire - Disease Index (CHAQ-DI). At an assessment visit, a JIA ACR30/50/70/90 response in comparison to Baseline was defined as: At least three of the six JIA ACR core components improving by at least 30 percent (%), 50%, 70%, or 90% respectively and no more than one of the remaining JIA ACR core components worsening by more than 30%.
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| Baseline JIA ACR30 (n=7) | 85.7 |
| Week 12 JIA ACR30 (n=7) | 100.0 |
| Week 24 JIA ACR30 (n=7) | 100.0 |
| Week 36 JIA ACR30 (n=7) | 100.0 |
| Week 48 JIA ACR30 (n=6) | 100.0 |
| Week 60 JIA ACR30 (n=6) | 100.0 |
| Week 72 JIA ACR30 (n=2) | 100.0 |
| Follow-Up JIA ACR30 (n=7) | 100.0 |
| Baseline JIA ACR50 (n=7) | 85.7 |
| Week 12 JIA ACR50 (n=7) | 100.0 |
| Week 24 JIA ACR50 (n=7) | 100.0 |
| Week 36 JIA ACR50 (n=7) | 100.0 |
| Week 48 JIA ACR50 (n=6) | 100.0 |
| Week 60 JIA ACR50 (n=6) | 100.0 |
| Week 72 JIA ACR50 (n=2) | 100.0 |
| Follow-Up JIA ACR50 (n=7) | 100.0 |
| Baseline JIA ACR70 (n=6) | 85.7 |
| Week 12 JIA ACR70 (n=7) | 100.0 |
| Week 24 JIA ACR70 (n=7) | 100.0 |
| Week 36 JIA ACR70 (n=7) | 100.0 |
| Week 48 JIA ACR70 (n=6) | 100.0 |
| Week 60 JIA ACR70 (n=6) | 100.0 |
| Week 72 JIA ACR70 (n=2) | 100.0 |
| Follow-Up JIA ACR70 (n=7) | 100.0 |
| Baseline JIA ACR90 (n=6) | 85.7 |
| Week 12 JIA ACR90 (n=7) | 85.7 |
| Week 24 JIA ACR90 (n=7) | 57.1 |
| Week 36 JIA ACR90 (n=7) | 71.4 |
| Week 48 JIA ACR90 (n=6) | 83.3 |
| Week 60 JIA ACR90 (n=6) | 66.7 |
| Week 72 JIA ACR90 (n=2) | 100.0 |
| Follow-Up JIA ACR90 (n=7) | 85.7 |
AEs and SAEs were recorded from the first day of tocilizumab administration until 4 weeks after administration of the last dose of tocilizumab.
| adverse events | Tocilizumab 8 mg/kg |
|---|---|
| Drug related AEs | 22 |
| Drug related SAEs | 0 |
| AEs of special interest | 2 |
| Drug-related AEs of special interest | 2 |
A participant was defined to show inactive disease if all of the following criteria were applied: 1) No joints with active arthritis (no joints with swelling and no joints with lack of motion), 2) No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, 3) No active uveitis, 4) ESR and/or CRP within normal range, and 5) Physician's global assessment of disease activity equals (=) 0 millimeters (mm) on a Visual analog scale (VAS).
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| Baseline(n=7) | 57.1 |
| Week 12 (n=7) | 42.9 |
| Week 24 (n=7) | 14.3 |
| Week 36 (n=7) | 42.9 |
| Week 48 (n=6) | 16.7 |
| Week 60 (n=6) | 33.3 |
| Week 72 (n=2) | 50.0 |
| Follow-Up (n=7) | 57.1 |
CR was defined as "clinical remission with medication (CRem)". A participant was in CR if inactive disease was observed for a minimum of 6 consecutive months.
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 0.0 |
| Screening (n=7) | 0.0 |
| Week 4 (n=7) | 0.0 |
| Week 8 (n=7) | 0.0 |
| Week 12 (n=7) | 0.0 |
| Week 16 (n=7) | 0.0 |
| Week 20 (n=7) | 0.0 |
| Week 24 (n=7) | 0.0 |
| Week 28 (n=7) | 14.3 |
| Week 32 (n=7) | 14.3 |
| Week 36 (n=7) | 14.3 |
| Week 40 (n=6) | 16.7 |
| Week 44 (n=6) | 16.7 |
| Week 48 (n=6) | 16.7 |
| Week 52 (n=6) | 16.7 |
| Week 56 (n=6) | 16.7 |
| Week 60 (n=6) | 0.0 |
| Week 64 (n=5) | 0.0 |
| Week 68 (n=3) | 0.0 |
| Week 72 (n=2) | 0.0 |
| Week 76 (n=1) | 0.0 |
| Follow-Up (n=7) | 0.0 |
The participant's treating physician provided a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line, score 0 represented 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end score 100 represented 'arthritis very active'. A higher score indicated more disease activity.
| mm | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 12.0 ± 30.4 |
| Week 12 (n=7) | 2.3 ± 2.9 |
| Week 24 (n=7) | 5.4 ± 6.1 |
| Week 28 (n=1) | 1.0 ± 0.0 |
| Week 32 (n=2) | 29.0 ± 8.5 |
| Week 36 (n=7) | 5.0 ± 7.9 |
| Week 48 (n=6) | 5.7 ± 8.2 |
| Week 60 (n=6) | 5.7 ± 8.7 |
| Week 72 (n=2) | 1.0 ± 1.4 |
| Follow-Up (n=7) | 5.0 ± 8.7 |
The participant or parent/guardian, as appropriate, provided a rating of the participant's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line Score 0 represented 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end score 100 represented 'very poor' (ie, maximum arthritis disease activity). A higher score indicated poorer well-being.
| mm | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 10.1 ± 20.0 |
| Week 12 (n=7) | 7.1 ± 8.1 |
| Week 24 (n=7) | 16.4 ± 19.9 |
| Week 28 (n=1) | 1.0 ± 0.0 |
| Week 32 (n=2) | 22.5 ± 24.7 |
| Week 36 (n=7) | 12.1 ± 18.4 |
| Week 48 (n=6) | 11.7 ± 13.9 |
| Week 60 (n=6) | 10.2 ± 13.8 |
| Week 72 (n=2) | 3.5 ± 4.9 |
| Follow-Up (n=7) | 9.7 ± 16.0 |
Joints with active arthritis were defined as joints with swelling or pain and limited of motion. The maximum number of joints with active arthritis was 71.The joint assessment was performed by an independent assessor who was not the treating physician and who was blinded to all other aspects of the participant's efficacy and safety data.
| joints | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 0.9 ± 2.3 |
| Week 12 (n=7) | 0.3 ± 0.8 |
| Week 24 (n=7) | 1.0 ± 2.6 |
| Week 28 (n=1) | 1.0 ± 0.0 |
| Week 32 (n=2) | 1.5 ± 0.7 |
| Week 36 (n=7) | 1.1 ± 2.2 |
| Week 48 (n=6) | 0.0 ± 0.0 |
| Week 60 (n=6) | 0.3 ± 0.8 |
| Week 72 (n=2) | 0.0 ± 0.0 |
| Follow-Up (n=7) | 0.3 ± 0.8 |
Joints with lack of movement were assessed. The maximum number of joints with lack of movement was 67. The joint assessment was performed by an independent assessor who was not the treating physician and who was blinded to all other aspects of the participant's efficacy and safety data.
| joints | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 1.4 ± 2.7 |
| Week 12 (n=7) | 2.6 ± 5.1 |
| Week 24 (n=7) | 2.4 ± 3.2 |
| Week 28 (n=1) | 1.0 ± 0.0 |
| Week 32 (n=2) | 5.5 ± 7.8 |
| Week 36 (n=7) | 1.7 ± 2.4 |
| Week 48 (n=6) | 2.7 ± 5.2 |
| Week 60 (n=6) | 1.8 ± 3.0 |
| Week 72 (n=2) | 0.0 ± 0.0 |
| Follow-Up (n=7) | 2.9 ± 4.8 |
ESR is a marker of inflammation and was measured as millimeters per hour (mm/h). Healthy individuals have low ESR. Higher ESR indicate inflammation.
| mm/h | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 4.9 ± 5.1 |
| Week 4 (n=7) | 3.0 ± 1.9 |
| Week 8 (n=7) | 2.9 ± 2.3 |
| Week 12 (n=7) | 3.0 ± 2.0 |
| Week 16 (n=7) | 8.6 ± 16.1 |
| Week 20 (n=7) | 2.6 ± 0.8 |
| Week 24 (n=7) | 2.7 ± 1.4 |
| Week 28 (n=5) | 3.4 ± 3.1 |
| Week 32 (n=7) | 4.3 ± 4.2 |
| Week 36 (n=7) | 4.3 ± 2.5 |
| Week 40 (n=6) | 2.0 ± 1.8 |
| Week 44 (n=6) | 2.7 ± 1.5 |
| Week 48 (n=6) | 3.8 ± 1.5 |
| Week 52 (n=6) | 3.2 ± 3.6 |
| Week 56 (n=6) | 2.3 ± 1.6 |
| Week 60 (n=6) | 10.2 ± 12.7 |
| Week 64 (n=5) | 3.2 ± 2.4 |
| Week 68 (n=3) | 10.0 ± 7.2 |
| Week 72 (n=2) | 4.5 ± 0.7 |
| Week 76 (n=1) | 2.0 ± 0.0 |
| Follow-Up (n=7) | 4.3 ± 2.8 |
The CHAQ-DI questionnaire consisted of 30 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain had at least two component questions and if applicable to the participant there were four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do). The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).
| score on a scale | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 0.0 ± 0.0 |
| Week 12 (n=7) | 0.04 ± 0.09 |
| Week 24 (n=7) | 0.14 ± 0.20 |
| Week 28 (n=1) | 0.00 ± 0.0 |
| Week 32 (n=2) | 0.19 ± 0.27 |
| Week 36 (n=7) | 0.13 ± 0.33 |
| Week 48 (n=6) | 0.00 ± 0.00 |
| Week 60 (n=6) | 0.21 ± 0.51 |
| Week 72 (n=2) | 0.00 ± 0.00 |
| Follow-Up (n=7) | 0.00 ± 0.00 |
Parents or participants rated participant's pain by placing a horizontal line on a VAS of 0 (no pain)- 100 mm (severe pain).
| mm | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 10.9 ± 21.8 |
| Week 12 (n=7) | 7.0 ± 10.0 |
| Week 24 (n=7) | 13.7 ± 16.7 |
| Week 28 (n=1) | 1.0 ± 0.0 |
| Week 32 (n=2) | 28.5 ± 17.7 |
| Week 36 (n=7) | 10.6 ± 15.9 |
| Week 48 (n=6) | 12.3 ± 13.6 |
| Week 60 (n=6) | 10.2 ± 13.8 |
| Week 72 (n=2) | 4.0 ± 5.7 |
| Follow-Up (n=7) | 9.9 ± 15.9 |
CRP an acute phase protein, is a marker of inflammation. CRP was measured as milligrams per deciliter (mg/dL).
| mg/dL | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=7) | 0.03 ± 0.01 |
| Week 4 (n=7) | 0.05 ± 0.07 |
| Week 8 (n=7) | 0.02 ± 0.02 |
| Week 12 (n=7) | 0.03 ± 0.01 |
| Week 16 (n=7) | 0.23 ± 0.54 |
| Week 20 (n=7) | 0.05 ± 0.07 |
| Week 24 (n=7) | 0.03 ± 0.02 |
| Week 28 (n=6) | 0.02 ± 0.02 |
| Week 32 (n=7) | 0.03 ± 0.02 |
| Week 36 (n=7) | 0.02 ± 0.02 |
| Week 40 (n=6) | 0.03 ± 0.02 |
| Week 44 (n=6) | 0.03 ± 0.02 |
| Week 48 (n=6) | 0.03 ± 0.02 |
| Week 52 (n=6) | 0.02 ± 0.02 |
| Week 56 (n=6) | 0.03 ± 0.02 |
| Week 60 (n=6) | 0.38 ± 0.90 |
| Week 64 (n=5) | 0.03 ± 0.03 |
| Week 68 (n=3) | 0.09 ± 0.10 |
| Week 72 (n=2) | 0.04 ± 0.04 |
| Week 76 (n=1) | 0.05 ± 0.0 |
| Follow-Up (n=7) | 0.05 ± 0.06 |
Collected over Adverse events were collected from the date of screening until the final Follow-Up Visit (up to 82 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab 8 mg/kg | — | 1/7 (14.3%) | 7/7 (100%) |
| Event | Tocilizumab 8 mg/kg |
|---|---|
| AppendicitisInfections and infestations | 1/7 |
| Event | Tocilizumab 8 mg/kg |
|---|---|
| GastroenteritisInfections and infestations | 4/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/7 |
| Upper respiratory tract infectionInfections and infestations | 3/7 |
| Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders | 3/7 |
| Abdominal painGastrointestinal disorders | 2/7 |
| Abdominal pain upperGastrointestinal disorders | 2/7 |
| NauseaGastrointestinal disorders | 2/7 |
| NeutropeniaBlood and lymphatic system disorders | 1/7 |
| Aortic valve incompetenceCardiac disorders | 1/7 |
| Mitral valve incompetenceCardiac disorders | 1/7 |
All participants who received at least one dose of study drug were included in the Safety Analysis Set.
| Age, Continuous(years) | Tocilizumab 8 mg/kg |
|---|---|
| Mean | 14.4 ± 3.2 |
| Gender(Participants) | Tocilizumab 8 mg/kg |
|---|---|
| Female | 6 |
| Male | 1 |
The record gives a start of Jan 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab